Bbt-877, multiple doses    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia1

85. Idiopathic interstitial pneumonia    [ 514 clinical trials,   377 drugs,   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways]
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03830125
(ClinicalTrials.gov)
February 13, 201931/1/2019Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy SubjectsA Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult SubjectsIdiopathic Pulmonary FibrosisDrug: BBT-877, Single dose;Drug: Placebo group;Drug: BBT-877, Multiple dosesBridge Biotherapeutics, Inc.KCRN Research, LLCCompleted19 Years55 YearsAll88Phase 1United States